文献速递冠心病血脂与心血管预防

多基因风险评分改善中国人群冠心病风险分层

A polygenic risk score improves risk stratification of coronary artery disease: a large-scale prospective Chinese cohort study.
PubMed 文献 · Eur Heart J · 2022-01-01

研究构建了包含540个遗传变异的冠心病多基因风险评分(PRS),并在41 271名中国前瞻性队列中评估其风险分层价值。在中位随访13.0年期间,高PRS(最高20%)个体冠心病风险约为最低20%的2.91倍,且PRS联合临床风险评分可小幅但显著改善风险预测与重分类。

要点

  • 高PRS(最高20%)者冠心病风险是最低20%的2.91倍(95%CI 2.43-3.49)。
  • PRS联合临床风险评分使C统计量提高1%,净重分类改善3.5%。
  • PRS可在各临床风险分层内进一步区分冠心病风险轨迹。

核心结论

  • PRS可将个体分为不同的冠心病风险轨迹,并在各临床风险分层内进一步细化风险分层,有助于识别高危个体进行靶向干预。

研究设计与样本

  • 利用东亚人群CAD及相关性状的大规模全基因组关联结果,通过荟萃分析方法构建包含540个遗传变异的PRS。
  • PRS在2800例冠心病患者和2055例对照的训练集中开发,并在包含41 271名个体的前瞻性队列中评估风险分层价值。

主要发现

  • 平均随访13.0年期间,共发现1303例新发冠心病事件。
  • 高PRS(最高20%)个体冠心病风险约为最低20%的2.91倍(HR 2.91,95%CI 2.43-3.49),终生风险分别为15.9%和5.8%。
  • PRS加入临床风险评分后,C统计量提高1%,净重分类改善3.5%。
  • 在各临床风险分层内,PRS均显示10年及终生冠心病风险的显著梯度。
  • 高PRS联合中间临床风险个体可达到高临床风险且中间PRS个体的风险水平(10年风险4.6% vs 4.8%,终生风险17.9% vs 16.6%)。

临床怎么用

  • 可将PRS作为临床风险评分的补充工具,用于中国人群冠心病一级预防中的风险细化分层。
  • 对中间临床风险且临床决策不确定的个体,结合高PRS有助于识别可能从干预中获益的高危人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: To construct a polygenic risk score (PRS) for coronary artery disease (CAD) and comprehensively evaluate its potential in clinical utility for primary prevention in Chinese populations. METHODS AND RESULTS: Using meta-analytic approach and large genome-wide association results for CAD and CAD-related traits in East Asians, a PRS comprising 540 genetic variants was developed in a training set of 2800 patients with CAD and 2055 controls, and was further assessed for risk stratification for CAD integrating with the guideline-recommended clinical risk score in large prospective cohorts comprising 41 271 individuals. During a mean follow-up of 13.0 years, 1303 incident CAD cases were identified. Individuals with high PRS (the highest 20%) had about three-fold higher risk of CAD than the lowest 20% (hazard ratio 2.91, 95% confidence interval 2.43-3.49), with the lifetime risk of 15.9 and 5.8%, respectively. The addition of PRS to the clinical risk score yielded a modest yet significant improvement in C-statistic (1%) and net reclassification improvement (3.5%). We observed significant gradients in both 10-year and lifetime risk of CAD according to the PRS within each clinical risk strata. Particularly, when integrating high PRS, intermediate clinical risk individuals with uncertain clinical decision for intervention would reach the risk levels (10-year of 4.6 vs. 4.8%, lifetime of 17.9 vs. 16.6%) of high clinical risk individuals with intermediate (20-80%) PRS. CONCLUSION: The PRS could stratify individuals into different trajectories of CAD risk, and further refine risk stratification for CAD within each clinical risk strata, demonstrating a great potential to identify high-risk individuals for targeted intervention in clinical utility.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Lu X, Liu Z, Cui Q, et al. A polygenic risk score improves risk stratification of coronary artery disease: a large-scale prospective Chinese cohort study. Eur Heart J. 2022. PMID: 35195259. doi:10.1093/eurheartj/ehac093

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。